TY - JOUR
T1 - Ghrelin Modulates Voltage-Gated Ca21 Channels through Voltage-Dependent and Voltage-Independent Pathways in Rat Gastric Vagal Afferent Neurons
AU - Goudsward, Hannah J.
AU - Ruiz-Velasco, Victor
AU - Stella, Salvatore
AU - Herold, Paul B.
AU - Holmes, Gregory M.
N1 - Publisher Copyright:
© 2024 by The American Society for Pharmacology and Experimental Therapeutics.
PY - 2024/11/1
Y1 - 2024/11/1
N2 - The orexigenic gut peptide ghrelin is an endogenous ligand for the growth hormone secretagogue receptor type 1a (GHSR1a). Systemic ghrelin administration has previously been shown to increase gastric motility and emptying. While these effects are known to be mediated by the vagus nerve, the cellular mechanism underlying these effects remains unclear. Therefore, the purpose of the present study was to investigate the signaling mechanism by which GHSR1a inhibits voltage-gated Ca21 channels in isolated rat gastric vagal afferent neurons using whole-cell patch-clamp electrophysiology. The ghrelin pharmacological profile indicated that Ca21 currents were inhibited with a log (Ic50) 5 -2.10 ± 0.44 and a maximal inhibition of 42.8 ± 5.0%. Exposure to the GHSR1a receptor antagonist (D-Lys3)-GHRP-6 reduced ghrelin-mediated Ca21 channel inhibition (29.4 ± 16.7% vs. 1.9 ± 2.5%, n 5 6, P 5 0.0064). Interestingly, we observed that activation of GHSR1a inhibited Ca21 currents through both voltage-dependent and voltage-independent pathways. We also treated the gastric neurons with either pertussis toxin (PTX) or YM-254890 to examine whether the Ca21 current inhibition was mediated by the Gai/o or Gaq/11 family of subunits. Treatment with both PTX (Ca21 current inhibition 5 15.7 ± 10.6%, n 5 8, P 5 0.0327) and YM-254890 (15.2 ± 11.9%, n 5 8, P 5 0.0269) blocked ghrelin’s effects on Ca21 currents, as compared with control neurons (34.3 ± 18.9%, n 5 8). These results indicate GHSR1a can couple to both Gai/o and Gaq/11 in gastric vagal afferent neurons. Overall, our findings suggest GHSR1a-mediated inhibition of Ca21 currents occurs through two distinct pathways, offering necessary insights into the cellular mechanisms underlying ghrelin’s regulation of gastric vagal afferents.
AB - The orexigenic gut peptide ghrelin is an endogenous ligand for the growth hormone secretagogue receptor type 1a (GHSR1a). Systemic ghrelin administration has previously been shown to increase gastric motility and emptying. While these effects are known to be mediated by the vagus nerve, the cellular mechanism underlying these effects remains unclear. Therefore, the purpose of the present study was to investigate the signaling mechanism by which GHSR1a inhibits voltage-gated Ca21 channels in isolated rat gastric vagal afferent neurons using whole-cell patch-clamp electrophysiology. The ghrelin pharmacological profile indicated that Ca21 currents were inhibited with a log (Ic50) 5 -2.10 ± 0.44 and a maximal inhibition of 42.8 ± 5.0%. Exposure to the GHSR1a receptor antagonist (D-Lys3)-GHRP-6 reduced ghrelin-mediated Ca21 channel inhibition (29.4 ± 16.7% vs. 1.9 ± 2.5%, n 5 6, P 5 0.0064). Interestingly, we observed that activation of GHSR1a inhibited Ca21 currents through both voltage-dependent and voltage-independent pathways. We also treated the gastric neurons with either pertussis toxin (PTX) or YM-254890 to examine whether the Ca21 current inhibition was mediated by the Gai/o or Gaq/11 family of subunits. Treatment with both PTX (Ca21 current inhibition 5 15.7 ± 10.6%, n 5 8, P 5 0.0327) and YM-254890 (15.2 ± 11.9%, n 5 8, P 5 0.0269) blocked ghrelin’s effects on Ca21 currents, as compared with control neurons (34.3 ± 18.9%, n 5 8). These results indicate GHSR1a can couple to both Gai/o and Gaq/11 in gastric vagal afferent neurons. Overall, our findings suggest GHSR1a-mediated inhibition of Ca21 currents occurs through two distinct pathways, offering necessary insights into the cellular mechanisms underlying ghrelin’s regulation of gastric vagal afferents.
UR - http://www.scopus.com/inward/record.url?scp=85206958591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85206958591&partnerID=8YFLogxK
U2 - 10.1124/molpharm.124.000957
DO - 10.1124/molpharm.124.000957
M3 - Article
C2 - 39187389
AN - SCOPUS:85206958591
SN - 0026-895X
VL - 106
SP - 253
EP - 263
JO - Molecular pharmacology
JF - Molecular pharmacology
IS - 5
ER -